Acute heart failure: diagnosis and management

hospital admission in people with acute heart failure due to left ventricular systolic dysfunction, once their condition has been stabilised â€“ for example, when intravenous diuretics are no longer needed. 1.5.3 Ensure that the person's condition is stable for typically 48 hours after starting or restarting beta-blockers and before discharging from hospital. 1.5.4 Offer an angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker if there are intolerable side effects) and an aldosterone antagonist during hospital admission to people with acute heart failure and reduced left ventricular ejection fraction. If the angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker) is not tolerated an aldosterone antagonist should still be offered. In February 2016, the Medicines and Healthcare products Regulatory Agency (MHRA) published advice on the concomitant use of spironolactone and renin- angiotensin system drugs in heart failure concerning the risk of potentially fatal hyperkalaemia. See the MHRA advice for more information. 1.5.5 Closely monitor the person's renal function, electrolytes, heart rate, blood pressure and overall clinical status during treatment with beta-blockers, aldosterone antagonists or angiotensin-converting enzyme inhibitors. 1.6 Valvular surgery and percutaneous intervention The recommendations on valvular surgery and percutaneous intervention have been replaced by the NICE guideline on heart valve disease. 1.7 Mechanical
